Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main trends shaping India’s pharmaceutical industry, while documenting BDR’s eye-catching achievements and areas of expertise, as well as the strategic alliances that the company is looking to establish in the US and Europe.
India-based manufacturers have been very successful on the international stage over the past 15 years, notably thanks to India’s competitive manufacturing cost advantage. Leveraging your long-standing industry experience, what have been some other key success factors that our readers might not know?
"To cope with price erosion in Europe and the US, we have decided to focus only on those products in which we hold a competitive edge and we are end-to-end integrated."
